arrow copy Created with Sketch. FightCRC Logo fcc-logo-light

Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location IO -centered Prior IO Allowed CRC-directed Status Drugs
NCT05328908
Phase 3
2022-04-14
Arkansas, United States
California, United States
Connecticut, United States
Florida, United States
Georgia, United States
Idaho, United States
Illinois, United States
Indiana, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
New Jersey, United States
North Carolina, United States
Ohio, United States
Pennsylvania, United States
South Carolina, United States
South Dakota, United States
Tennessee, United States
Texas, United States
Virginia, United States
Wisconsin, United States
Argentina
Australia
Austria
Belgium
Canada
Chile
China
Czechia
France
Germany
Italy
Japan
Korea, Republic of
Netherlands
Poland
Puerto Rico
Singapore
Spain
Sweden
Switzerland
Taiwan
No
No
Yes
Recruiting
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
NCT03642067
Phase 2
2018-08-22
Maryland, United States
Yes
No
Yes
Recruiting
Nivolumab, Relatlimab, Opdivo
NCT02966548
Phase 1
2016-11-17
Japan
No
Yes
No
Active, not recruiting
Nivolumab, Relatlimab, Opdivo
NCT02465060
Phase 2
2015-06-08
Alabama, United States
Alaska, United States
Arizona, United States
Arkansas, United States
California, United States
Colorado, United States
Connecticut, United States
Delaware, United States
District of Columbia, United States
Florida, United States
Georgia, United States
Hawaii, United States
Idaho, United States
Illinois, United States
Indiana, United States
Iowa, United States
Kansas, United States
Kentucky, United States
Louisiana, United States
Maine, United States
Maryland, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
Mississippi, United States
Missouri, United States
Montana, United States
Nebraska, United States
Nevada, United States
New Hampshire, United States
New Jersey, United States
New Mexico, United States
New York, United States
North Carolina, United States
North Dakota, United States
Ohio, United States
Oklahoma, United States
Oregon, United States
Pennsylvania, United States
Rhode Island, United States
South Carolina, United States
South Dakota, United States
Tennessee, United States
Texas, United States
Utah, United States
Vermont, United States
Virginia, United States
Washington, United States
West Virginia, United States
Wisconsin, United States
Wyoming, United States
Guam
Puerto Rico
Yes
Yes
Yes
Active, not recruiting
Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib
NCT01968109
Phase 1/Phase 2
2013-10-23
California, United States
Colorado, United States
Florida, United States
Illinois, United States
Maryland, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
Missouri, United States
New York, United States
Oregon, United States
Pennsylvania, United States
Texas, United States
Washington, United States
Australia
Austria
Canada
Denmark
Finland
France
Germany
Italy
Japan
Netherlands
Norway
Spain
Switzerland
United Kingdom
Yes
Yes
No
Active, not recruiting
BMS-986213, Nivolumab, Relatlimab, Opdivo